Business
Estrigenix secures seed financing to advance Marquette- and UWM-sourced estrogen receptor-beta platform
Milwaukee-based Estrigenix Therapeutics, a biotechnology company developing selective estrogen receptor-beta (ERβ) therapeutics, has announced the first...
Novartis Q2'26: AOC FDA filing and FSHD biomarker progress as H2 catalyst slate builds
Novartis AG (NYSE: NVS) held its Novartis Q2 2026 earnings call on July 21, 2026, during which executives detailed the company's first FDA submission for an...
Lupin spins out PRMT5 and SOS1 oncology programs into equity-backed Kaveri
Lupin Limited (BSE: 500257, NSE: LUPIN) has moved two clinical-stage oncology assets off its own balance sheet and into a newly formed company, in a...
Engitix taps Lonza's ADC platform to target cancer through extracellular matrix discovery
Basel, Switzerland-based Lonza (SIX: LONN) has granted London-based Engitix Therapeutics a single-target license to its antibody-drug conjugate technology...
MaxCyte licenses cell-engineering platform to Genentech across multiple programs
MaxCyte, Inc. (Nasdaq: MXCT), a Rockville, Maryland-based cell-engineering company, has entered a multi-platform technology license with Genentech, a member...
Samsung Biologics expands into peptide manufacturing with USD 1.8b PolyPeptide acquisition
Samsung Biologics (KRX: 207940) has launched an all-cash public tender offer to acquire Switzerland-based PolyPeptide Group AG (SIX: PPGN) at CHF 44.31 per...
Tempus acquires Personalis for USD 1.5b to consolidate MRD leadership in precision oncology
Tempus AI, Inc. (Nasdaq: TEM) has agreed to acquire Fremont, California-based Personalis, Inc. (Nasdaq: PSNL) in a transaction valued at $1.5 billion in...
Incyte adds Halozyme's ENHANZE tech to first-in-class myeloproliferative neoplasm therapy
Halozyme Therapeutics (Nasdaq: HALO) has entered a global collaboration and license agreement with Incyte (Nasdaq: INCY) to apply Halozyme's ENHANZE drug...
Latigo files to IPO with non-opioid pain therapy entering late-stage development
Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company developing non-opioid pain medicines, filed for an initial public...
BlossomHill files for Nasdaq IPO with EGFR-resistant lung cancer program
BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage oncology company whose lead drug candidate targets a treatment-resistant lung cancer...
DBV Tech raises USD 150m as BLA imminent for peanut-allergy patch
DBV Technologies S.A. (Euronext: DBV, Nasdaq: DBVT), a Châtillon, France-based late-stage biopharmaceutical company, has filed a refreshed at-the-market...
Vogenx seeks public funding to advance SGLT1 candidate in metabolic disorders
Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage biopharmaceutical company developing a treatment for a metabolic condition with no FDA-approved therapies,...
Inhibrx secures up to USD 325m in additional venture debt to fund pipeline through key catalysts
San Diego-based Inhibrx Biosciences (Nasdaq: INBX) entered into an amended loan agreement with Oxford Finance LLC, expanding its credit facility to a total...
J&J Q2 2026 Earnings Call: Milvexian timeline, FireFly Bio acquisition, and H2 pipeline catalysts
Johnson & Johnson (NYSE: JNJ) held its JNJ Q2 2026 earnings call on July 15, 2026, during which executives detailed plans to acquire South San...
Jasper expands immunology reach Kira acquisition, USD 132m PIPE round
Jasper Therapeutics, Inc. (Nasdaq: JSPR) has completed its acquisition of Cambridge, Massachusetts-based Kira Pharmaceuticals in an all-stock transaction,...
The AllSci Brief
Systematic R&D and deal news. Daily.